Relapse of Systemic Juvenile Idiopathic Arthritis after Influenza Vaccination in a Patient Receiving Tocilizumab
- 8 August 2012
- journal article
- case report
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 19 (10), 1700-1702
- https://doi.org/10.1128/cvi.00309-12
Abstract
We report the case of a patient with systemic juvenile idiopathic arthritis (s-JIA) receiving tocilizumab (TCZ) who experienced relapses of s-JIA after receiving influenza vaccination. Systemic symptoms of s-JIA might be masked during TCZ therapy. Careful observation with the monitoring of serum interleukin (IL)-18 and IL-6 levels may be useful.Keywords
This publication has 6 references indexed in Scilit:
- Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumabModern Rheumatology, 2012
- Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritisVaccine, 2012
- Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic DiseaseThe Journal of Rheumatology, 2011
- Immunogenicity of Influenza Vaccine in Children With Pediatric Rheumatic Diseases Receiving Immunosuppressive AgentsThe Pediatric Infectious Disease Journal, 2011
- Should children under treatment for juvenile idiopathic arthritis receive flu vaccination?Archives of Disease in Childhood, 2007
- Influenza immunization in children with chronic arthritis: a prospective study.1993